We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Sanofi gets rights to Glenmark's TRPV3 antagonists for pain
08 Dec 2015
Executive Summary
Glenmark Pharmaceuticals SA (division of Indian drug company Glenmark Pharmaceuticals Ltd.) has granted Sanofi-Aventis exclusive rights in certain countries to its transient receptor potential vanilloid receptor 3 (TRPV3) antagonists for chronic pain. The deal includes the Phase I candidate GRC15300 for diabetic neuropathic pain and osteoarthritic pain.
Deal Industry
Pharmaceuticals
Deal Status
Final
Deal Type
Alliance
Co-Marketing
Co-Promotion
Includes Royalty or Profit Split Information
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?